SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-014380
Filing Date
2022-05-19
Accepted
2022-05-18 19:07:58
Documents
57
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 732329
2 ex31-1.htm EX-31.1 17342
3 ex32-1.htm EX-32.1 7641
  Complete submission text file 0001493152-22-014380.txt   4284965

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT endv-20220331.xsd EX-101.SCH 44058
5 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT endv-20220331_cal.xml EX-101.CAL 42157
6 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT endv-20220331_def.xml EX-101.DEF 194444
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT endv-20220331_lab.xml EX-101.LAB 356583
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT endv-20220331_pre.xml EX-101.PRE 261395
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 550298
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 22940785
SIC: 2834 Pharmaceutical Preparations